Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label safety study of shortened versus standard uptitration of Allergovit grasses
2012-001914-41Phase 2Completed
- Sponsor
- Allergopharma
- Start
- Jul 2012
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Allergovit Grasses in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by Allergopharma. Primary endpoint: Safety and tolerability during uptitration. Started Jul 2012; status: completed.
02
Drugs
Allergovit Grasses
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2012-001914-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001914-41.